ADMA Biologics Investigated for Alleged Securities Fraud

Investors Encouraged to Contact Law Firm After Channel Stuffing Claims

Apr. 13, 2026 at 10:35am

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a stack of financial documents, a calculator, and a gavel on a clean, monochromatic seamless background, conceptually representing the legal and financial implications of the ADMA Biologics investigation.An investigation into alleged channel stuffing at ADMA Biologics raises concerns about transparency and accountability in the biopharmaceutical industry.NYC Today

Leading securities law firm Bleichmar Fonti & Auld LLP has announced an investigation into ADMA Biologics, Inc. for potential violations of federal securities laws. The investigation centers around allegations that ADMA Biologics' reported 20% revenue growth in 2025 was driven by a channel stuffing scheme to mask deteriorating demand for its flagship product ASCENIV.

Why it matters

The investigation into ADMA Biologics' alleged channel stuffing practices could have significant implications for the company and its investors. If proven true, the scheme could constitute securities fraud and lead to legal action, fines, and reputational damage for the biopharmaceutical firm.

The details

According to the investigation, Culper Research published a report in March 2026 alleging that ADMA Biologics induced one of its distributors to 'stock excess ASCENIV by offering rebates and extended payment terms' in order to meet revenue expectations. This allegedly allowed ADMA Biologics to book revenue that 'was never there,' with the company reporting 20% growth in 2025 when it would have actually experienced a 3% decline without the channel stuffing.

  • On March 24, 2026, Culper Research published its report on ADMA Biologics' alleged channel stuffing.
  • From March 23, 2026 to March 25, 2026, ADMA Biologics' stock price declined 29% in response to the report.

The players

ADMA Biologics, Inc.

An end-to-end commercial biopharmaceutical company focused on manufacturing and developing specialty biologics, including its flagship product ASCENIV.

Culper Research

An investigative research firm that published a report alleging ADMA Biologics engaged in a channel stuffing scheme to inflate its 2025 revenue.

Bleichmar Fonti & Auld LLP

A leading international law firm representing plaintiffs in securities class actions and shareholder litigation, which has announced an investigation into ADMA Biologics.

Got photos? Submit your photos here. ›

What’s next

The judge in the case will decide on whether to allow a class action lawsuit against ADMA Biologics to proceed based on the findings of the investigation.

The takeaway

This case highlights the importance of transparency and accurate financial reporting, as allegations of channel stuffing and securities fraud can have serious consequences for public companies and their investors. It also underscores the role of independent research firms and securities law firms in holding corporations accountable.